CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 1,068,800,000	$ 1,963,200,000
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(19,400,000)	(4,100,000)
Net Cash Provided by (Used in) Financing Activities	(497,400,000)	(775,500,000)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings	851,000,000.0	1,238,100,000
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation And Amortization Of Leased Assets	97,700,000	96,300,000
Depreciation and amortization	320,600,000	371,000,000.0
Stock compensation	77,600,000	52,600,000
Asset Impairment Charges	1,200,000	0
Deferred income taxes	(35,500,000)	(85,500,000)
Other Operating Activities, Cash Flow Statement	3,700,000	2,300,000
Change in assets and liabilities (net of effects of acquisitions):
Increase in accounts receivable (net)	(21,400,000)	(265,000,000.0)
Increase (Decrease) in Unbilled Contract Receivable	123,900,000	100,300,000
Increase in inventories	35,700,000	17,500,000
Decrease in accounts payable	131,900,000	(44,300,000)
Increase (Decrease) in Deferred Revenue	(6,200,000)	37,700,000
Increase (Decrease) in Prepaid Expense and Other Assets	25,900,000	31,000,000.0
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities	(349,400,000)	(139,600,000)
Net cash provided by operating activities	928,500,000	1,644,800,000
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash payments for laboratory-related assets	(260,500,000)	(192,600,000)
Proceeds from sale of assets	1,100,000	2,700,000
Proceeds from Sale of Equity Method Investments	400,000	0
Payments to Acquire Equity Method Investments	(4,700,000)	(11,900,000)
Net Cash Provided by (Used in) Investing Activities	(815,600,000)	(222,800,000)
Payments to Acquire Businesses, Net of Cash Acquired	(554,900,000)	(34,100,000)
Net cash used for investing activities	(815,600,000)	(222,800,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments of Other Long-term Debt	0	375,000,000.0
Payment, Tax Withholding, Share-based Payment Arrangement	37,400,000	43,000,000.0
Net proceeds from issuance of stock to employees	19,100,000	26,600,000
Payments of Dividends	(66,700,000)	0
Payments for Repurchase of Common Stock	400,000,000.0	368,500,000
Other Financing Cash Flows	12,400,000	15,600,000
Net cash provided by (used for) financing activities	(497,400,000)	(775,500,000)
Repayments of Senior Debt	0	1,000,000,000
Proceeds from Issuance of Senior Long-term Debt	0	1,000,000,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(403,900,000)	642,400,000
Cash and cash equivalents at beginning of period	1,472,700,000
Cash and cash equivalents at end of period	1,068,800,000
Business Acquisition [Line Items]
Proceeds from Sales of Business, Affiliate and Productive Assets	0	13,100,000
Proceeds from Hedge, Investing Activities	$ 3,000,000.0	$ 0